--- title: "Organon Issues Supplemental Disclosures on Sun Pharma Merger" type: "News" locale: "en" url: "https://longbridge.com/en/news/293076946.md" description: "Organon issued supplemental disclosures regarding its merger with Sun Pharma to address litigation risks. The update details $700 million in estimated synergies, board deliberations on the $13.50 per-share offer, and financial projections through 2030. This aims to provide shareholders clearer valuation data ahead of the July 23 special meeting. Analysts maintain a Hold rating with a $14 target, while AI analysis notes neutral sentiment due to weakened financial performance despite the acquisition premium." datetime: "2026-07-17T21:38:15.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/293076946.md) - [en](https://longbridge.com/en/news/293076946.md) - [zh-HK](https://longbridge.com/zh-HK/news/293076946.md) --- # Organon Issues Supplemental Disclosures on Sun Pharma Merger ### TipRanks Welcomes a New ETF – NYSE:RANK - TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE. - RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies. Organon ( (OGN) ) has issued an announcement. On April 26, 2026, Organon agreed to be acquired through a merger in which it will become a wholly owned subsidiary of Sun Pharmaceutical Holdings USA, Inc., and subsequently filed a definitive proxy statement on June 17, 2026, ahead of a July 23, 2026 special shareholder meeting. In response to a July 6, 2026 lawsuit alleging incomplete and misleading proxy disclosures and seeking to block the shareholder vote, Organon, while rejecting the claims as meritless, opted on July 17, 2026 to voluntarily supplement its proxy materials with additional detail on estimated synergies, board deliberations, valuation inputs and financial projections to reduce litigation risk and avoid delays to the Sun Pharma transaction. The supplemental disclosure reveals Organon’s preliminary estimate of $700 million in cost synergies across commercial, procurement, R&D and corporate functions that were presented to Sun Pharma in January 2026. It also outlines the board’s consideration of Sun Pharma’s initial $13.50 per-share offer versus alternative strategic paths, and provides investors with additional Morgan Stanley reference data, forward-looking projections for revenue, adjusted EBITDA and free cash flow through 2030, and updated figures for share count, net debt and adjusted LTM EBITDA, potentially giving shareholders a clearer basis to assess the merger’s valuation and strategic rationale. The most recent analyst rating on (OGN) stock is a Hold with a $14.00 price target. To see the full list of analyst forecasts on Organon stock, see the OGN Stock Forecast page. **Spark’s Take on OGN Stock** According to Spark, TipRanks’ AI Analyst, OGN is a Neutral. The score is primarily weighed down by weakened financial performance—sharp TTM revenue decline, lower net profitability, and high leverage—despite strong cash generation. Technicals are constructive with an uptrend, and valuation is supported by a moderate P/E and very high dividend yield. A major positive offset is the announced all-cash acquisition, which provides a clear premium path but carries deal-completion risk. To see Spark’s full report on OGN stock, click here. **More about Organon** Organon & Co. is a pharmaceutical company focused on women’s health, biosimilars and established brands, operating globally with a portfolio that spans fertility, contraception, and other specialty therapeutics. The company’s business model emphasizes commercializing established products while pursuing strategic partnerships and transactions to strengthen its position in specialty and women’s health markets. **Average Trading Volume:** 7,160,341 **Technical Sentiment Signal:** Buy **Current Market Cap:** $3.54B ### Related Stocks - [OGN.US](https://longbridge.com/en/quote/OGN.US.md) - [RANK.US](https://longbridge.com/en/quote/RANK.US.md) - [MS.US](https://longbridge.com/en/quote/MS.US.md) - [MS-O.US](https://longbridge.com/en/quote/MS-O.US.md) - [MS-Q.US](https://longbridge.com/en/quote/MS-Q.US.md) - [MS-E.US](https://longbridge.com/en/quote/MS-E.US.md) - [MS-I.US](https://longbridge.com/en/quote/MS-I.US.md) - [MS-L.US](https://longbridge.com/en/quote/MS-L.US.md) - [MS-P.US](https://longbridge.com/en/quote/MS-P.US.md) - [MS-A.US](https://longbridge.com/en/quote/MS-A.US.md) - [MS-F.US](https://longbridge.com/en/quote/MS-F.US.md) - [MS-K.US](https://longbridge.com/en/quote/MS-K.US.md) ## Related News & Research - [Organon Announces Quarterly Dividend | OGN Stock News](https://longbridge.com/en/news/294516961.md) - [Organon & Co. 2026: Revenue $1.56B, EPS $0.4— 10-Q Summary](https://longbridge.com/en/news/294511535.md) - [Organon & Co. Shareholders Clear Sun Pharma Merger Deal](https://longbridge.com/en/news/293638590.md) - [Organon holds special shareholder meeting on merger agreement proposal](https://longbridge.com/en/news/293669016.md) - [Orographic Financial Advisors LLC Acquires New Holdings in Organon & Co. $OGN](https://longbridge.com/en/news/294494554.md)